MDM2 expression, combined with increased p53 expression, is associated with reduced survival in several cancers, but is particularly of interest in renal cell carcinoma (RCC) where evidence suggests the presence of tissue-specific p53/MDM2 pathway defects. We set out to identify MDM2-interacting proteins in renal cells that could act as mediators/targets of MDM2 oncogenic effects in renal cancers. We identified the non-metastatic cells 2, protein; NME2 (NDPK-B, NM23-B/-H2), a nucleoside diphosphate kinase, as an MDM2-interacting protein using both a proteomic-based strategy [affinity chromatography and tandem mass spectrometry [MS/MS] from HEK293 cells] and a yeast two-hybrid screen of a renal carcinoma cell-derived complementary DNA library. The MDM2-NME2 interaction is highly specific, as NME1 (87.5% amino acid identity) does not interact with MDM2 in yeast. Specific NME proteins display well-documented cell motility and metastasis-suppressing activity. We show that NME2 contributes to motility suppression under conditions where MDM2 is expressed at normal physiological/low levels. However, up-regulation of MDM2 in RCC cells abolishes the ability of NME2 to suppress motility. Significantly, when MDM2 expression is down-regulated in these cells using small interfering RNA, the motility-suppressing activity of NME2 is rescued, confirming that MDM2 expression causes the loss of NME2 cell motility regulatory function. Thus MDM2 up-regulation in renal cancer cells can act in a dominant manner to abrogate the function of a potent suppressor of motility and metastasis. Our studies identify a novel protein-protein interaction between MDM2 and NME2, which suggests a mechanism that could explain the link between MDM2 expression and poor patient survival in RCC.
Introduction
The MDM2 gene encodes a proto-oncogene best understood for its critical role as a negative regulator of the p53 tumour suppressor (reviewed in 1). MDM2 interacts with p53, targets it for proteasomal degradation and inhibits its transcriptional activity and thus, p53 is a major target of MDM2 oncogenic activity. However, considerable evidence exists which suggests that MDM2 can exert p53-independent oncogenic effects on cells (reviewed in 2). Studies in NIH3T3 cells have shown that naturally occurring splice variants of MDM2 that lack the ability to bind to p53 retain transforming activity (3) . Additional evidence from in vivo studies of mice expressing an MDM2 transgene from a b-lactoglobulin promoter have demonstrated abnormal mammary development and cell cycle deregulation in both p53 wild-type and null backgrounds (4) . Further evidence has been provided by studies of mice that over-expressed MDM2 from the MDM2 promoter, which developed a different spectrum of tumours compared with p53-null mice (5), regardless of their p53 status. MDM2 expression has also been shown to abrogate the growth inhibitory activities of transforming growth factor-beta1 in a p53-independent manner in cells in culture (6) . More recently, we have shown that MDM2 monoubiquitylates dihydrofolate reductase, altering cellular sensitivity to methotrexate and inhibiting dihydrofolate reductase activity in tumour cells in a p53-independent manner (7), thus implicating MDM2 in the regulation/deregulation of one carbon metabolism with potentially far-reaching consequences.
Not only is up-regulation of MDM2 capable of promoting p53-independent oncogenic effects, but up-regulation of MDM2, regardless of p53 status, has been shown to be a significant factor determining outcome in a range of common cancers. Increased MDM2 expression has been found to be associated with poor outcome in studies of prostate, bladder, oesophageal and renal cancers (8) (9) (10) (11) . Up-regulation of MDM2 sometimes occurs in combination with high levels of p53 and this is most strikingly observed in renal cell carcinomas (RCCs) where there is a strong positive association between MDM2 and p53 expression (P 5 0.00004) (8) . Such a strong association between co-expression of p53 and MDM2 requires a better understanding of tissue-specific defects in individual cancer types, which may modulate the regulation/deregulation of this pathway. For example, while up-regulation of mutant p53 and MDM2 are associated with poor outcome in bladder cancer, no such strong link with co-expression has been observed (10) . Nonetheless, it is clear that, at least in some cancers, over-expression of MDM2 acts to promote cancer by acting upon unidentified adjunct pathways in addition to its well documented essential role in negatively regulating p53.
Most activities of MDM2 have been ascribed to protein-protein interactions (reviewed in ref. 12 ). To identify targets for oncogenic adjunct activities of MDM2, we have sought to identify proteins expressed in renal and renal cancer cells that interact with MDM2 and which either have intrinsic oncogenic/tumour-suppressive properties or which alter the activity of parts of the p53/MDM2 pathways in a potentially oncogenic manner. Using two quite different approaches, one based upon affinity chromatography and mass spectrometry and the other involving a yeast two-hybrid screen using a complementary DNA (cDNA) library from a RCC line (786-0), we identified the non-metastatic cells 2, protein (NME2; also known as NDPK-B, NM23B, NM23-H2 or Puf, EC 2.7.4.6) as a novel MDM2-binding protein.
Although most studies of motility and metastasis and the NME family have focused upon NME1, specific studies of NME2 have demonstrated that it suppresses motility (13) and metastasis (14) . Interestingly, recent studies have also implicated MDM2 as a promoter of motility/invasion and up-regulation of MDM2 has also been linked with metastatic potential (15, 16) . We show here that not only does MDM2 interact in a highly specific manner with NME2, but also MDM2 and NME2 have opposing effects on motility. Most significantly for MDM2-mediated cancer progression, our results demonstrate that high levels of MDM2 abolish the motility-suppressing activity of NME2 in a p53-independent manner. This discovery suggests that there may be a role for up-regulation of MDM2 in promoting intrinsic tumour cell motility and through this promoting metastasis in vivo. Thus, our studies provide a potential mechanistic basis that would link MDM2 expression with poor prognosis. Since NME up-regulation and down-regulation are associated with different stages in tumour development (17,18), our results with NME2 and MDM2 provide novel insights into critical pathways in carcinogenesis.
Materials and methods
Plasmids and antibodies hMDM2:pCMVneobam and pCMVneobam have been described previously (19, 20) . The human NME2 cDNA and pTBc601c containing the apical domain of Mycobacterium tuberculosis Cpn60.1 were kindly provided by D.Halverson and P.Tormay, respectively. MDM2 expressed from pQE30 was described previously (21) . Human N-terminal and C-terminal halves of MDM2 were constructed from hMDM2:pCMVneobam by polymerase chain reaction (PCR) and cloned into the BamH1-Pst1 sites of pQE30 and pQE32, respectively, using the following primers (all synthesized by Eurofins MWG Operon, Ebersberg, Germany) N-terminal half: 5#-GAGAGGATCCCCCGCCGCCAC-CATGTGCAATACCAACATGTCTGTAC-3# and 5#GAGGATCCCTG-CAGCTAGAGAGATTCAACTTCAAATTCTAC-3#; C-terminal half: 5#GAGGATCCCTGTAGAATTTGAAGTTGAATCTCTC-3# and 5#GAG-GATCCCTGCAGCTAGGGGAAATAAGTTAGCACAATC-3#.
pGADT7-Rec-Large T AD was constructed by homologous recombination in yeast according to the manufacturer's instructions (Clontech Matchmaker III system). pGAD-NME2 was prepared as follows. The cDNA was amplified with primers 5#-CTCGAATTCCCCGGACCATGGCCAACCTGG-3# and 5#-GCTGTT-GGATCCACCTCTTATTCATAGACCC-3# and then an EcoRI, BamHI fragment was subcloned into pFLAG-CMV-6b (Sigma-Aldrich Company Ltd, Gillingham, UK). This fragment was then cloned following blunting of the EcoRI site into the EcoRI (blunt) and BamHI sites of pGADT7. NME2 was subcloned into pCEP4 (Invitrogen Ltd, Paisley, UK) from pFLAG-CMV-6b using HindIII and BamHI restriction endonucleases. The NME1 cDNA was prepared from a placental cDNA by PCR with primers 5#-GAGCGGCCGCG-GACCATGGCCAACTGTGAGCGTACC-3# and 5#-GTGGGATCCCCTCCT-GTCATTCATAGATCC-3# followed by subcloning into pFLAG-CMV-6b and PGADT7 as for NME2. NME1 was subcloned into pCEP4 from pFLAG-CMV-6b using NotI and BamHI restriction endonucleases.
Constructs expressing HA-tagged NME1 and NME2 were generated by PCR from pCEP4-NME1 and two templates using primer sets: 5#-GAGAGCGGCCGCCACCATGGGCTACCCATACGATGTTCCAGATTACGC-TATGGTGCTACTGTCTACTTTAGGG-3# and 5#-GTGGGATCCCCTCCTGT CATTCATAGATCC-3# for NME1 and 5#-GAGAGCGGCCGCCACCATGG GCTACCCATACGATGTTCCAGATTACGCTATGGCCAACCTGGAGCGCA-CC-3# and 5#-GCTGTTGGATCCACCTCTTATTCATAGACCC-3# for NME2 followed by restriction digest with NotI and BamHI and cloning into the pCEP4 vector linearized with the same restriction endonucleases.
The N-terminally elongated form of NME1 has been generated by introduction of a Kozak consensus sequence (CGGACC) in front of the ATG codon situated 75 bp before the usual start codon of the NME1 coding sequence by PCR from human placental cDNA using primers: 5#-GATGAATTCGGAC-CATGGTGCTACTGTCTACTTTAG-3# and 5#-GTGGGATCCCCTCCTGT-CATTCATAGATCC-3# followed by subcloning into pFLAG-CMV-6b and pCEP4 as for NME1. This generated a longer form of NME1, which has an additional N-terminal 25 amino acids, allowing for clear discrimination between endogenous and transfected NME1 forms.
pGBKT7-MDM2 was prepared by subcloning a blunt ended NcoI fragment from pBlueBac-His2 (Invitrogen) into the blunted SalI site of pGBKT7. pSKBBV-NME2 used for in vitro-binding assays was prepared by excising and blunt ending a HindIII, BamHI fragment from pFLAG-CMV-6b-NME2 and cloning this into the EcoRV site of pSKBBV (19) . The NME2 kinase mutant K12Q was prepared by PCR from pCEP4-NME2 with primers: 5#-GAGCGGCCGCGGACCATGGCCAACCTG GAGCGCACCTTCATCGCCATCCAGC-3# and 5#-GCTGTTGGATCCA-CCTCTTATTCATAGACCC-3# then cloned into the NotI and BamHI sites of pCEP4. Mutant H118F was prepared similarly using primers: 5#-GAGGATCCTTATTCATAGACCCAGTCATGAGCACAAGACTTGTA GTCAACCAGTTCTTCAGGCTTAAACCATAGGCTGATTTCTTTTTCA GCACTTTTTACTGAATCACTGCCAAAAATG-3# and 5#-GAGCGGCC-GCGGACCATGGCCAACCTGGAGCGCACCTTCAT-3#. All plasmid constructs were sequenced prior to use.
The mouse monoclonal antibodies for b-actin [C-2, used as a protein loading control in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)], NME1 (sc-465) and the goat polyclonal antibody (L-15) for NME2 (used in western analysis) were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA. The rabbit antibody (Ab31019) used to detect both NME1 and NME2 was purchased from Abcam, Cambridge, UK. The mouse monoclonal antibodies used in western analysis for MDM2 (Ab-1, clone IF-2), the isotype control antibody for immunoprecipitation for p53 (Ab-4, PAb246) and b-galactosidase, (Ab-1, used as a transfection efficiency control), were purchased from EMD Biosciences, San Diego, CA. Anti-HA epitope monoclonal antibodies used were 16B12 (Cambridge Bioscience Ltd, Cambridge, UK) for immunoprecipitation and 12CA5 (Roche Applied Science, Burgess Hill, UK) for immunoblotting. Anti-CD20 (leu 16) used as an isotype control was from BD Biosciences, Oxford, UK. Anti-GFP mouse monoclonal was obtained from Roche. Secondary antibodies were anti-mouse and anti-rabbit (GE Healthcare Life Sciences, Little Chalfont, UK) and anti-goat (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Cell culture and transfection H1299 (p53 null) cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum. MCF-7 (p14 ARF null) and HEK 293 cells were maintained in Dulbecco's modified Eagle's medium-N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid modification supplemented with 10% fetal calf serum and 2 mM L-glutamine. UOK 117 cells, hereafter referred to as 117 cells are derived from a RCC and express relatively low levels of wild-type p53 and MDM2 (20) . 1.27 cells are derived from 117 cells by two rounds of transfection and cloning with two different empty vector plasmids (pCEP4, HygR and pCMVneobam, NeoR) and display spontaneously up-regulated p53 and MDM2 (21) . 117 and 1.27 cells were maintained in Eagle's MEM supplemented with 2mM L-glutamine, 1.5 g/l sodium bicarbonate, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum. p53À/À, MDM2À/À mouse embryo fibroblasts were maintained in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 0.1 mM non-essential amino acids and 10% fetal calf serum.
Cells were transiently transfected using either 3 ll Genejuice (Novagen) per microgram of DNA with empty vectors added to ensure equal DNA content in transfections. Small interfering RNA (siRNA) was delivered to cells using Lipofectamine 2000 according to the manufacturer's instructions. siRNAs (Dharmacon, Lafayette, CO) were as follows: for MDM2; MDM2#1 (5#-GCCACAAAUCUGAUAGUAU-3#), MDM2#9 (5#-GCCAGUAUAUUAU-GACUAA-3#), NME2#7 (5#-GCGAGAUCAUCAAGCGCUU-3#), NME2#8 (5#-GAAAUCAGCCUAUGGUUUA-3#), scrambled siRNA (5#-GGACG-CAUCCUUCUUAAU-3#), RISC-free siRNA#1 (catalogue no. D001220-01).
Preparation of columns and mass spectroscopy
Columns were prepared and analysed as described previously (7) .
Western blot analysis
Column fractions and cell pellets were analysed essentially as we have described previously (22) . Signals were detected by chemiluminescence and recorded using a Kodak IS4000MM image station or autoradiography. Typically, 50 lg samples were analysed.
In vitro-binding assay In vitro-binding assays were performed essentially as described previously (19) . Briefly, full length or truncation mutants of His 6 -tagged MDM2 expressed in XL-1 Escherichia coli (Stratagene, Cedar Creek, TX) were purified as described previously by binding to nickel-nitrilotriacetic acid agarose beads and then incubated at 30°C for 3 h, with in vitro translated 35 S Cys/Met labelled NME2 (TNT; Promega, Southampton, UK). As a control for specificity, a His 6 -tagged 23 kDa fragment of the mycobacterial heat shock protein CPN60.1 (kindly provided by Dr Peter Tormay) was used. Following incubation, beads were washed four times with 0.5 ml buffer D (23) (containing phenylmethylsulfonyl fluoride and dithiothreitol) supplemented with 75 mM imidazole and then samples were resuspended in 30 ll of Laemmli-loading buffer (24) and analysed by SDS-PAGE. Gels were fixed prior to vacuum drying and fluorography using Amplify TM (GE Healthcare).
Yeast two-hybrid screening Yeast two-hybrid screening was performed as recommended by the manufacturer of the Matchmaker III system (Clontech-Takara Bio Europe, SaintGermain-en-Laye, France). All pGAD vectors used were transformed into the AH109 strain and all pGBKT7 vectors were transformed into the Y187 strain so that combinations could be generated through mating. A library was constructed from total RNA extracted from 786-0 cells (American Type Culture Collection, Manassas, VA) using RNA-bee (Biogenesis Ltd, Poole, UK) and messenger RNA was then purified using RNeasy kit (Qiagen, Crawley, UK). cDNA was recombined with 3 lg of the pGADT7-Rec in AH109 yeast strain according to the Matchmaker III protocol and plated on one hundred and ninety-seven 150 mm leucine drop out agar plates to select for transformants. Transformation efficiency obtained was 1 to 2 Â 10 6 colonies/1 lg of pGADT7-Rec plasmid. The library (titer 5 5.8 Â 10 8 /ml) was harvested and frozen at À80°C.
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Immunoprecipitation analysis This was performed as described previously (7, 22) .
Motility assay
Typically 1 Â 10 4 to 5 Â 10 4 cells were seeded into each Boyden chamber (VWR International, Lutterworth, UK) that was inserted into a 24-well plate containing $300 ll of cell culture media and incubated for 18 h prior to analysis essentially as described (25) . To determine the number of cells that had passed through the chamber membrane, the membrane was divided into four or more grids. Digital images of each grid were counted manually. Three chambers were counted for each sample and the average number of cells that passed through to the outer chamber membrane has been represented in graphical format.
Cell growth/proliferations assay These were performed as described previously (26) . Briefly, cells were seeded in quadruplicate into 96-well plates and media were replenished every second day. Wells were incubated for 3 h with 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (Sigma) at the indicated time points and the optical absorbance at 590 nm was measured using a Thermo-Multiskan plate reader. Alternatively, 10 000 cells were seeded per well of a 24-well plate in triplicate per condition/time point as described previously (26) .
Results
We used two different approaches to identify MDM2-interacting proteins expressed in kidney-derived cells and identified the nucleoside diphosphate kinase B isoform (NME2) through both. One approach utilized affinity chromatography on a Nickel sepharose column coated with recombinant His 6 -tagged human MDM2 to which extracts from HEK 293 cells were then applied. MDM2-interacting proteins were eluted with an imidazole gradient, resolved by SDS-PAGE and identified by mass spectrometry. We have recently used this approach to identify other MDM2 interactions [(7) and supplementary Figure 1A , available at Carcinogenesis Online]. Figure 1A shows the result of staining for total protein on a single lane from a 1D SDS-PAGE resolved MDM2 column fraction eluted with 168-210 mM imidazole. A control column prepared with bovine serum albumin instead of His 6 -MDM2 displays a different elution profile with most of the MDM2 eluting at a lower concentration of imidazole in the range 42-84 mM [see (7) ]. Following 1D SDS-PAGE protein bands were subjected to mass spectroscopic analysis and one of these was identified as NME2 as indicated in Figure 1A . NME2 was identified (ProteinPilot) with 99% confidence, and with 25.7% sequence coverage in three peptides with one of these distinguishing NME2 from NME1. Figure 1B shows that NME1 and NME2 display a high degree of homology, being 87.5% identical at the amino acid level. Subsequently, fractions were analysed by western blotting with an antibody that is specific for NME2 and which only weakly cross reacts with NME1 (see Figure 1C and supplementary Figures 1B and 2 , available at Carcinogenesis Online) and with an antibody specific for NME1 (sc-465). Note that it is also possible to distinguish between NME1 and NME2 because they migrate differently, with NME1 migrating more slowly than NME2 as supplementary Figure 3A and B, available at Carcinogenesis Online, illustrate. The enzyme encoded by the NME1 and NME2 genes, NDPK is formed from homo-and heterohexameric NDPK subunits and thus detection of either NME1 or NME2, the most abundant NME family members would result in a high probability of finding the other isoform on the same column fractions (reviewed in ref. 27 ). Figure 1C also shows that while NME1 and NME2 copurify with MDM2 in the MDM2 column, both elute with non-specifically bound proteins in the bovine serum albumin control column as do all other proteins including endogenous MDM2. Western blot analyses of the columns using antibodies for a number of known MDM2-binding proteins indicated that they also copurified with MDM2 whereas actin did not (supplementary Figure  1A , available at Carcinogenesis Online). In parallel studies, we generated a cDNA from a RCC cell line (786-0) and used this to create a library for a yeast two-hybrid screen. Two independent yeast colonies were identified on quadruple dropout media that were found to contain NME2 by DNA sequence analysis. Figure 2A and B shows that NME2 interacts in a yeast two-hybrid screen with MDM2. Since interactions in the yeast two-hybrid assay are unlikely to depend on protein oligomerisation, we also tested cDNA for NME1 side by side with NME2 for the ability to interact with MDM2 and as Figure 2A shows, it does not. Given the high degree of homology between NME1 and NME2, this demonstrates that there is considerable specificity to the interaction of NME2 with MDM2.
The results from the yeast two-hybrid screen suggest that the interaction of MDM2 with NME2 is mediated by direct protein-protein interactions. To test this further we performed in vitro-binding assays similar to those we have described previously (19, 28) . Figure 3A shows that NME2 interacts with full-length recombinant His 6 -MDM2 and preferentially with the amino terminus of MDM2. Note that although there is a weak signal with the carboxy-terminus, there is considerably more protein on the beads for the C-terminal fragment of MDM2 than the N-terminal fragment (see Figure 3B ) and hence, we conclude that the interaction is mediated primarily through direct protein-protein interaction of NME2 with the N-terminal half of MDM2. We also examined whether we could detect evidence of MDM2-NME2 interaction in cell lysates. Figure 3C shows the results of immunoprecipitation experiments performed in H1299 cells transfected with expression vectors for MDM2 and an HA-tagged NME1 or NME2. The results indicate that MDM2 can be co-precipitated with NME2, but not with NME1 and thus these results further support our earlier data suggesting that there is a high degree of specificity to this interaction. We also examined whether endogenous MDM2 and NME2 could be coimmunoprecipitated and Figure 3D shows that immunoprecipitation of NME (NME1/2) indeed leads to coprecipitation of MDM2 (note that we used an NME1/2 cross-reacting antibody since none of the NME2-specific antibodies that we tested worked well for immunoprecipitation).
MDM2 is an E3 ubiquitin ligase that catalyses both the ubiquitylation of heterologous proteins and also its own ubiquitylation (reviewed in ref. 1). Interaction of NME2 with MDM2 might promote the ubiquitylation (possibly leading to degradation) of NME2 or alter the stability of MDM2. However, we have found that MDM2 has no effect upon the expression level of NME2 and under these conditions, there is no apparent effect of NME2 upon MDM2 levels either following ectopic expression in H1299 cells or siRNA-mediated down-regulation of the endogenous proteins in H1299 or MCF-7 cells as Figure 4A and B shows, respectively. Thus, NME2 is not a target of MDM2-promoted proteasomal degradation.
MDM2 is a highly phosphorylated protein (29) and so, it might be suggested that MDM2 could represent a substrate for the putative protein kinase activity of NME2. Although this activity has been argued to be an in vitro artefact (30), we had noted that in experiments where high transfection efficiency was achieved, ectopic expression of NME2 led to reduced steady-state levels of MDM2 protein (as illustrated in supplementary Figure 2 , available at Carcinogenesis Online). We also noticed in later siRNA transfection experiments that suppression of NME2 expression led to a moderate increase in MDM2 steady-state levels (for example, see data discussed later in Figure 6 ). To determine whether the effect of NME2 transfection leading to reduced MDM2 steady-state levels was kinase dependent, we transfected mutants of NME2 that lack kinase activity. As illustrated in supplementary Figure 2 , available at Carcinogenesis Online, we found that the NME2-mutant K12Q which lacks detectable NDPK activity (31) has a comparable effect to wild-type NME2 on MDM2 steady-state expression. We have also observed similar results with another mutant (H118F) that directly affects an active site histidine (data not shown). These experiments also indicated that the effect on MDM2 steady-state levels could be reversed by using a proteasome inhibitor (MG132) and consequently, it is probable that this effect is due to altered protein stability. These experiments also suggest that the impact of NME2 on MDM2 steady-state levels is independent of any putative protein kinase activity (30) .
NME2 is one of a pair of NDPKs that have been identified as 'nonmetastatic proteins', which have been shown to suppress cell motility NME2 and MDM2 interact and have opposing effects on cell motility (13, 14, 32, 33) . More recently, MDM2 has been demonstrated to promote cell motility (15, 16) and therefore, we investigated the effect of manipulating the levels of both of these proteins upon cell motility. Since increased MDM2 expression in renal cancer promotes more aggressive disease [reduced patient survival, (8) and see ref. 34 for review], we wanted to study the effect of increasing MDM2 expression on motility in renal cells. In particular, we wanted to determine whether such up-regulation might lead to loss of motility suppression mediated by NME2 and thus might provide an explanation for the association between MDM2 expression and patient outcomes. Stable ectopic expression of MDM2 is not trivial in most cell lines as the cells cannot tolerate such expression (35) and so not surprisingly, we have been unable to generate renal cancer cell lines that stably express MDM2 from a heterologous promoter. Nevertheless, we have identified spontaneous clones of cells derived from a p53 wild-type RCC line 117 that express increased levels of MDM2 designated 1.27 (21) (see Figure 5A ). This derivative line not only displays increased MDM2 expression, but also exhibits significantly increased cell motility as we have shown previously and as Figure 5A also demonstrates. We have also included H1299 cells since these represent an example of a heterologous line that also expresses relatively low levels of MDM2 and lacks p53. All three lines express comparable levels of endogenous NME1 and NME2. Note that the difference between 117 and 1.27 motility is not due to any difference in cell growth/proliferation between these isogenic cells as the cell lines grow at similar rates (see Figure 5B) . We have not included data on the proliferation of H1299s as these are unrelated cells and thus such comparison would not be informative.
We next investigated whether manipulating the endogenous levels of NME2 and MDM2 expression would result in altered cell motility and how differing levels of MDM2 expression impact on this. As Figure 6A shows for H1299 cells that express low levels of MDM2 and are p53 null, reducing the level of the metastasis suppressor protein NME2 results in an apparent increase in motility. In addition, siRNA-mediated down-regulation of MDM2 results in a highly significant reduction in cell motility. These results demonstrate that in this tumour cell line, which expresses relatively low levels of MDM2, both MDM2 and NME2 contribute to the overall motility phenotype. This conclusion is further supported by combined siRNA transfection Fifteen milligrams of HEK 293 clarified cell lysate was passed over a column coated with 4 mg of recombinant His 6 -MDM2 as described previously (7) . Following extensive washing to remove non-specific proteins in a buffer containing 10 mM imidazole, the MDM2 (and interacting proteins) was removed from the column with an increasing concentration of imidazole using a linear imidazole gradient. Eluted fractions were resolved by SDS-PAGE and analysed for total protein by staining with brilliant blue G-colloidal stain. (A) SDS-PAGE analysis of a peak MDM2-containing fraction #5 [see (7) and refer to supplementary Figure 1 for NME2 and MDM2, which results in these opposing effects cancelling out on another. Note that the histograms demonstrate that the observed effects of modulating NME2 and/or MDM2 on motility are not due to any change in cell proliferation since there is no apparent impact on proliferation under any of the conditions used. Since the H1299 cells used in this experiment lack p53, these results also show that the effect of both NME2 and MDM2 upon motility that we have observed is p53 independent and also that the opposing contributions of these proteins to regulating motility is not simply restricted to renal cells.
MDM2 up-regulation in renal cancer is linked with poor patient survival (8) , and metastasis is the major risk factor for death for these patients. Therefore, we hypothesized that up-regulation of MDM2 would promote increased cell motility and that this up-regulation would render cells unable to respond to the motility-suppressing action of NME2. Figure 6B and C show the results of a Boyden chamber motility experiment in which siRNA has been used to down-regulate NME2 and MDM2 expression separately and in combination in isogenic renal cells that express differing levels of MDM2. In Figure 6B , 117 cells which express relatively low levels of MDM2, transfection with MDM2 siR-NA has no effect on motility in contrast with NME2 siRNA transfection which significantly increases cell motility. However, in 1.27 cells that express increased MDM2 ( Figure 6C ) there is no longer any response to NME2 siRNA-mediated suppression, but these cells now respond to transfection with MDM2 siRNA by displaying significantly reduced cell motility. Moreover, once MDM2 levels are reduced by siRNA, these cells then become sensitive to NME2 and hence combined siRNA down-regulation results in increased motility suggesting that the presence of high levels of MDM2 in these cells is the dominant determinant of this phenotype. To confirm that these results are not due to any offtarget effects of the siRNAs used, we repeated these experiments on 117 and 1.27 cells with additional siRNAs for MDM2 and NME2 and obtained essentially the same results as supplementary Figure 4 , available at Carcinogenesis Online, shows. We conclude that not only do MDM2 and NME2 have opposing effects on cell motility, but NME2 and MDM2 interact and have opposing effects on cell motility furthermore MDM2 up-regulation renders cells unresponsive to the motility-suppressing action of NME2. Thus, increased expression of MDM2 increases motility and compromises the motility regulatory function of a key suppressor of metastasis. These results suggest a potential mechanism by which MDM2 up-regulation in RCC may promote more aggressive tumour behaviour.
Discussion
We have identified several novel MDM2-interacting proteins using affinity chromatography and nano-liquid chromatography-electrospray ionisation-tandem mass spectrometry. One of these, NME2 (NM23B, NDPK-B) was also identified in parallel using a yeast two-hybrid cm dish plasmids as indicated. Forty-eight hours after transfection, cells were harvested and 3 mg of clarified lysate was used for immunoprecipitation. 16B12 was used to precipitate HA-tagged proteins and MDM2 was precipitated with SMP14. Anti-p53 Ab-4 (PAb246) mouse monoclonal antibody was used as an isotype control since cells are p53 null. Following resolution of the precipitated proteins by SDS-PAGE, samples were analysed by western blot using the indicated antibodies. (D) Clarified lysate from HEK 293 cells was subjected to immunoprecipitation with the indicated antibodies (MDM2: SMP14, isotype control anti-CD20 leu16, NME1/2: Ab31019) and then analysed by western blotting with an antibody to MDM2 (IF-2).
R.Polań ski et al.
screen for MDM2-interacting proteins expressed in renal cancer cells. NME2 (NDPK, EC 2.7.4.6) encodes NDPK-B a member of a family of ubiquitous nucleoside diphosphate kinases, which are defined by their ability to catalyse the transfer of c-phosphate from nucleoside 5#-triphosphates to nucleoside 5#-diphosphates (36) . In addition, NME2 has also been implicated in the suppression of both motility and metastasis (13, 14) , though as discussed below, the mechanism of this remains unclear.
The best-studied member of this gene family is NME1 (NM23 A/NDPK-A), a paralogue of NME2 (88% amino acid identity) and the first member of the gene family to be identified (33) . NME1 is upregulated both in primary tumours in mouse models of cancer (17) and in a number of DNA microarray studies of human cancer (18) , which suggests that it may possess oncogenic properties. In addition, NME1 is also a metastasis suppressor (see refs. 37,38), displaying antimetastatic activity in mouse models and suppressing tumour cell motility in vitro (33) . These seemingly conflicting functions are nicely supported by observations made in transgenic mice which display up-regulation in primary tumours (suggestive of oncogenicity) and down-regulation in metastases (suggestive of metastasis suppression), respectively (17) . How these different associations and functions are mediated is a puzzle that remains to be solved.
Our studies indicate that there is a high degree of specificity to the interaction that we have identified, NME1 does not detectably interact with MDM2 in the yeast system and was not detected by tandem mass spectrometry analysis of MDM2 containing affinity chromatography fractions nor were NME1 cDNAs detected in the yeast two-hybrid library screen. However, by following a more sensitive approach using antibodies to specifically detect NME1, we have detected copurification of NME1 with MDM2 in fractions from an MDM2 affinity column as Figure 1C shows. Moreover, we did not detect MDM2 co-immunoprecipitation with HA-NME1 but did with HA-NME2 (see Figure 3C ). Since NME1 and NME2 are identical to NDPK-A and B, respectively, and form enzymatically active homo-and heterohexamers (39, 40) , one likely explanation is that the NME1 detected by western blotting represents the presence of NME complexes containing predominantly NME2 but also containing NME1.
One issue that we have not pursued extensively is the putative function of NMEs as protein kinases. MDM2 is known to be a highly phosphorylated protein and the interaction that we have detected with NME2 might suggest that MDM2 is a substrate for such NME-dependent protein kinase activity. However, as illustrated in supplementary Figure 2 , available at Carcinogenesis Online, we have found that the limited ability of NME2 to alter the steady-state level of MDM2 is independent of its kinase domain since the K12Q mutant lacks detectable NDPK activity (31) . Moreover, while NME2 has been shown to display limited protein kinase activity in vitro, the significance of this has been questioned leading some to conclude that NMEs do not behave as true protein kinases in vivo (30) .
Our central aim has been to identify mechanism/s through which MDM2-mediated tumour progression leads to more aggressive and MCF-7 cells were chosen since they represent respectively a commonly used p53-null non small cell lung carcinoma cell line and a commonly used p53-wild-type breast cancer-derived cell line and thus, observed effects are not restricted to any one cell type. Note that the exposure chosen emphasizes the differences in MDM2 levels in transfected cells and thus, the relatively low levels of endogenous MDM2 are not apparent. Results are from a single typical experiment that has been repeated on at least three separate occasions. NME2 and MDM2 interact and have opposing effects on cell motility
disease. An obvious process that could mediate this would be through increasing cell motility/invasion and/or metastasis. Given the evidence that NMEs are metastasis suppressors that act through suppression of cell motility it was obvious that we should investigate this.
Non-directional or random motility is one of the better in vitro indicators of metastatic potential (41, 42) and so, we have performed Boyden chamber motility assays to measure this in cells in which MDM2 and/or NME2 levels were manipulated. We not only found that MDM2 and NME2 display opposing p53-independent effects, but moreover, cells which expressed high levels of MDM2 were no longer responsive to NME2-mediated suppression of motility. Since down-regulation of MDM2 in these cells restored the motilitysuppressing activity of NME2, we suggest that MDM2 expression acts in a dominant manner to override the motility (and metastatic?) suppressing activity/function of NME2. This result may have significant implications for cancers where MDM2 up-regulation is linked with poor outcomes such as renal, bladder, prostate and oesophageal cancers (8) (9) (10) (11) . Studies of NME in a variety of cancers have often been ambiguous. Part of the reason for this may be that as studies in mice have shown, NME expression is increased in primary tumours and reduced in metastases (17) . Moreover, these same studies demonstrated that deletion of one allele leads to compensatory upregulation of another, thus partially restoring NDPK activity in cells. Therefore, it may not be a surprise that in some cancer samples, NMEs are up-regulated and in others are down-regulated. Also, there may be issues in some studies with some antibodies for different NMEs crossreacting. In one of the largest studies of NME expression in RCC in which 95 cases were examined using antibodies specific for NME1 and NME2, it was found that loss of NME1, but not of NME2 was associated with reduced survival (43) , although some smaller studies have not confirmed this association (44) . Loss of heterozygosity of NME1 has been reported in more than one study of renal cancers and probably contributes to down-regulation (45, 46) . Nevertheless, no large survey examining NME expression in RCC has been reported and so it is difficult to make confident statements regarding patterns of NME expression in this disease. Based upon our functional analysis, it seems worthwhile to pursue a study in which expression of NMEs and MDM2 are examined for correlations with metastatic disease. For example, it would be particularly interesting if it was found that MDM2-expressing tumours showed no or less frequent loss of NME2.
Clearly, the question arises of how MDM2 promotes motility/ overcomes the motility-suppressing activity of NME2. The studies presented here do not address either of these points, primarily because the individual mechanisms of action of MDM2 and NME2 are not yet known. As far as MDM2 is concerned, two recent studies have suggested that it promotes motility through promoting degradation of either E-cadherin (16) or Slug (15) . However, neither of these studies addressed the key question of whether the ability of MDM2 to promote motility/invasion/metastasis depended upon its ubiquitin ligase activity. Our recent studies have shown that both wild-type and RING finger mutant MDM2 [the MDM2 RING finger is required for MDM2 E3 ubiquitin-ligase activity (47) ] can promote cell motility and invasion (21) and therefore, the mechanism of action of MDM2-mediated increased motility and invasion remains unclear. With respect to NMEs, which have a longer history of studies demonstrating cell motility/metastasis suppressing activities, the mechanism of action also remains unclear (recently reviewed in ref. 27 ). NMEs are fairly small proteins, human NME1 and NME2 are both 152 amino acids long, and critical amino acid residues required for nucleoside kinase activity span much of this length. Perhaps surprisingly, therefore, it appears that for this family of proteins partly defined/identified by their nucleoside diphosphate kinase activity/domain [Group I i.e. NME 1-4 (27) ], this enzymatic activity is apparently dispensable for their function as suppressors of motility/metastasis (48) (49) (50) . If the NDPK activity does not mediate metastasis suppression as these authors have concluded, then a number of other activities that have been ascribed to NMEs/NDPKs might determine this [see (27, 51) for recent discussions of the additional activities and evidence relating to them]. In addition to enzymatic activities of various kinds, some effects of NMEs may also derive directly from protein-protein interactions (52) . The fact remains though, that none of the many described additional enzymatic activities of NMEs have been demonstrated to determine suppression of cell motility/metastasis. On the other hand, several consequences of NME expression have been described and these may yet lead to the identification of the proximal mechanism/s of action (53) . Until the mechanism of action of NME-mediated cell motility/metastasis suppression becomes clear, it will be difficult to determine how MDM2 abrogates the activity of NME2 that is responsible for regulating cell motility/metastasis.
Our studies were initiated primarily because of the unusual phenotype/outcome correlation in RCC where not only has MDM2 expression been found to be associated with poor outcome, but this is almost always associated with high levels of p53 protein (P , 0.00004) [(8) , reviewed in refs. 34 and 54] . It has been suggested that this is due to a novel dominant-negative mechanism that inactivates p53 in renal cells (55) . However, our own studies and those of others have suggested that p53 is functionally intact and is regulated by MDM2 in these cells (20, 56, 57) , although this does still beg the question of how can high levels of both p53 and MDM2 coexist. Since MDM2 is associated with a significantly worse outcome than is observed for p53 up-regulation alone, it appears probable that raised MDM2 expression may directly promote poor outcome in RCC and this is likely to be the result of MDM2 interaction with target protein/s. Our studies have revealed a novel interaction between MDM2 and a suppressor of metastasis and motility; NME2 and suggest that high levels of MDM2 as observed in some poor prognosis RCCs result in loss of NME2-mediated suppression of motility. This provides a potential mechanism for MDM2-promoted tumour progression since loss of NME2 suppression of cell motility in vitro would probably be manifested in vivo by increased metastatic potential.
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